The Safety and Tolerability of Pirfenidone for BOS After HCT

Summary

This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant.

Timeline

Start

2018-03-01

Primary completion

2022-02-27

Completion

2022-04-27

Publications

• Sharifi H, Moss CT, Musa Z, Bell A, O'Donnell C, Borges CH, Matthaiou EI, Johnston L, Galban CJ, Sheshadri A, Yanik G, Cheng GS, Hsu JL. Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease. Blood Adv. 2025 Oct 14;9(19):5024-5037. doi: 10.1182/bloodadvances.2025016122.
• Matthaiou EI, Sharifi H, O'Donnell C, Chiu W, Owyang C, Chatterjee P, Turk I, Johnston L, Brondstetter T, Morris K, Cheng GS, Hsu JL. The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. Bone Marrow Transplant. 2022 Aug;57(8):1319-1326. doi: 10.1038/s41409-022-01716-4. Epub 2022 May 31.

Drugs

Indications